Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

4Total
P 1 (1)
P 2 (2)
P 3 (1)

Trial Status

Recruiting3
Not Yet Recruiting1
Terminated1
Active Not Recruiting1
Unknown1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07492225Phase 2Active Not Recruiting

Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial

NCT04865939Phase 3Recruiting

Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma

NCT05494411Unknown

Named Patient Program for Mitomycin for Pyelocalyceal Solution

NCT05874921Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

NCT06120387Recruiting

Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer

NCT03606174Phase 2Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

NCT05979909Phase 1Not Yet RecruitingPrimary

Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma

Showing all 7 trials

Research Network

Activity Timeline